How does the IL-2 Surpass ELISA kit contribute to the mechanism research and efficacy evaluation of cytokine immunotherapy?

1. What are the core functions of IL-2 in the immune system and its cellular sources?

Interleukin-2 (IL-2) is a pleiotropic cytokine that plays a central role in the initiation, effector phase, and regulation of adaptive immune responses. Initially discovered as a T-cell growth factor, it was the first cytokine approved for cancer immunotherapy. In terms of cellular sources, IL-2 is primarily produced by activated CD4+ helper T cells (Th0, Th1) and CD8+ cytotoxic T cells (Tc1). When the T-cell receptor (TCR) recognizes an antigen and receives co-stimulatory signals (e.g., via CD28), transcription factors such as NFAT, AP-1, and NF-κB are activated, inducing transient transcription and secretion of IL-2. Additionally, dendritic cells, B cells, and innate lymphoid cells can also produce small amounts of IL-2. Its secretion pattern is primarily autocrine and paracrine, acting on immune cells within the local microenvironment.

2. How does IL-2 mediate diverse immune effects through its receptor complex?

The biological functions of IL-2 are achieved through high-affinity binding to its cell surface receptor complex. This receptor consists of three subunits: the α-chain (CD25), β-chain (CD122), and common γ-chain (γc, CD132). IL-2 first binds to the α-chain, followed by recruitment of the β-chain and γc-chain to form a high-affinity complex, thereby activating downstream signaling pathways such as JAK-STAT (primarily JAK1/JAK3-STAT5), PI3K-AKT, and MAPK. Depending on receptor expression, IL-2 exerts differential effects on various immune cell subsets: 1. Promoting effector cell proliferation and function: For naïve T cells, effector T cells, and natural killer (NK) cells expressing intermediate-affinity receptors (βγc dimers), IL-2 is a key driver of clonal expansion, survival, and enhanced cytotoxic activity. It also promotes B-cell proliferation, antibody production, and plasma cell differentiation. 2. Maintaining regulatory T-cell stability and function: For regulatory T cells (Tregs) that highly express CD25 (α-chain), IL-2 is essential for their survival, homeostasis, and immunosuppressive functions. This "dual regulatory" property—affecting both effector and regulatory cells—gives IL-2 both immunostimulatory and immunoregulatory roles, with the net effect depending on dose, timing, and the local microenvironment.

3. What is the development history of IL-2-based drugs and the challenges faced?

Recombinant human IL-2 (aldesleukin) was approved by the FDA in 1992 for treating metastatic renal cell carcinoma and melanoma, marking the dawn of cytokine immunotherapy. However, clinical use of native IL-2 faces significant challenges: 1. Extremely short half-life: Its half-life after intravenous injection is only minutes, necessitating frequent high-dose administration. 2. Narrow therapeutic window and significant toxicity: High-dose IL-2 can cause severe systemic side effects, including capillary leak syndrome, hypotension, and organ dysfunction, largely due to widespread activation of CD25-expressing endothelial cells. 3. Potential activation of immunosuppressive Tregs: Because Tregs have higher affinity for IL-2, conventional doses may preferentially expand Tregs, thereby suppressing antitumor immune responses. To overcome these limitations, novel IL-2 variant drugs focus on: ① Extended half-life: PEGylation or fusion with antibody Fc fragments improves pharmacokinetics. ② Selective bias: Genetic engineering (e.g., "non-α" variants) weakens CD25 binding, selectively activating effector T cells and NK cells expressing βγc receptors while sparing Tregs and endothelial cells. ③ Development of IL-2 receptor agonist antibodies: Antibodies specifically targeting IL-2Rβ (CD122) directly and selectively activate downstream pathways.

4. What are the key applications of the IL-2 Surpass ELISA Kit in basic research and drug development?

In exploring IL-2 biology and evaluating drug efficacy, the high-sensitivity, high-specificity IL-2 Surpass ELISA Kit is an indispensable tool. Its applications span: 1. Immune response mechanism studies: In vitro T-cell or NK-cell activation assays, or in vivo infection, tumor, or autoimmune models, this kit quantifies IL-2 protein levels in serum, plasma, or cell culture supernatants at various timepoints, revealing correlations between IL-2 kinetics and immune response intensity. 2. Treg and effector cell function studies: By measuring IL-2 levels alongside cell sorting and functional assays, researchers can investigate IL-2's role in Treg homeostasis and CD8+ T-cell or NK-cell activation. 3. Preclinical evaluation of novel IL-2 variants: For PEGylated IL-2, non-α-biased IL-2 variants, or IL-2 agonist antibodies, the kit enables: a) Pharmacokinetic analysis of serum IL-2 post-administration; b) Assessment of drug effects on tumor microenvironment IL-2 levels; c) Use as a pharmacodynamic biomarker reflecting immune system activation. 4. Quality control and potency assessment of cell therapies (e.g., CAR-T): During CAR-T manufacturing, IL-2 secretion by activated T cells serves as a key quality control metric for functional activity.

5. Which manufacturers provide the IL-2 Surpass ELISA Kit?

Hangzhou Start Biotech Co., Ltd. has independently developed the "Human Interleukin-2 (IL-2) Surpass ELISA PairSet Kit" (Catalog No.: S0H2001), a core reagent set designed for developing high-sensitivity, high-specificity quantitative assays for human IL-2. This product provides rigorously paired and validated capture and detection antibody pairs, enabling users to efficiently construct high-performance sandwich ELISA systems for accurate and reliable quantification of IL-2 in human serum, plasma, cell culture supernatants, and tissue homogenates. It is a critical tool for assessing T-cell immune responses, immunoregulation, and tumor immunology research.

Technical Support: We provide detailed documentation, including antibody specificity validation data, recommended ELISA protocols (coating, blocking, detection conditions), buffer formulations, and standard curve guidelines. Our technical team offers expert method development and optimization support.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-value core reagents for immunology research, clinical translation, and diagnostic development. For more information about the "Human Interleukin-2 (IL-2) Surpass ELISA PairSet Kit" (Catalog No. S0H2001), technical documentation, or trial requests, please contact us anytime.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.